

# Michele I Morris

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4540385/publications.pdf>

Version: 2024-02-01

51  
papers

1,121  
citations

393982

19  
h-index

414034

32  
g-index

53  
all docs

53  
docs citations

53  
times ranked

1875  
citing authors

#	ARTICLE	IF	CITATIONS
1	National Landscape of Human Immunodeficiency Virus-Positive Deceased Organ Donors in the United States. <i>Clinical Infectious Diseases</i> , 2022, 74, 1010-1019.	2.9	7
2	Successful Treatment of Disseminated Disease Due to Highly Resistant <i>Aspergillus calidoustus</i> with a Novel Antifungal Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, aac0220621.	1.4	4
3	COVID-19 in solid organ transplant recipients: A systematic review and meta-analysis of current literature. <i>Transplantation Reviews</i> , 2021, 35, 100588.	1.2	159
4	Lower incidence of Cytomegalovirus reactivation following post-transplant cyclophosphamide HLA mismatched unrelated donor transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 1017.e1-1017.e1.	0.6	5
5	Viral kinetics and outcomes of adenovirus viremia following allogeneic hematopoietic cell transplantation. <i>Clinical Transplantation</i> , 2021, 35, e14481.	0.8	2
6	476. A Global Survey of Countermeasures Against the COVID-19 Pandemic Among Solid Organ Transplant Centers. <i>Open Forum Infectious Diseases</i> , 2021, 8, S339-S340.	0.4	0
7	1347. Comparison Between SARS-Cov-2, non-SARS-Cov-2 Coronavirus, Influenza and RSV Infections Among Solid Organ Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2021, 8, S760-S761.	0.4	0
8	454. Impact of Covid-19 on Infectious Disease Fellows in the United States: A National Survey to Identify Targets for Intervention. <i>Open Forum Infectious Diseases</i> , 2021, 8, S328-S330.	0.4	0
9	Failure of atovaquone prophylaxis for prevention of toxoplasmosis in hematopoietic cell transplant recipients. <i>Transplant Infectious Disease</i> , 2020, 22, e13198.	0.7	4
10	Clarifying the HOPE Act landscape: The challenge of donors with false-positive HIV results. <i>American Journal of Transplantation</i> , 2020, 20, 617-619.	2.6	13
11	Hepatitis flare in hepatitis B core antibody positive kidney recipients treated with rituximab. <i>Transplant Infectious Disease</i> , 2020, 22, e13211.	0.7	1
12	A How-to Guide to Building a Robust SARS-CoV-2 Testing Program at a University-Based Health System. <i>Academic Pathology</i> , 2020, 7, 2374289520958200.	0.7	4
13	Reduced immunogenicity of the adjuvanted recombinant zoster vaccine after hematopoietic cell transplant: a pilot study. <i>Blood Advances</i> , 2020, 4, 4618-4622.	2.5	15
14	Antimicrobial resistance and recurrent bacterial urinary tract infections in hospitalized patients following kidney transplantation: A single-center experience. <i>Transplant Infectious Disease</i> , 2020, 22, e13337.	0.7	5
15	Clinical real-world experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients. <i>Clinical Transplantation</i> , 2020, 34, e13866.	0.8	48
16	Successful Treatment of Invasive Fungal Infection Due to Highly Resistant <i>Aspergillus calidoustus</i> in an Allogeneic Hematopoietic Cell Transplant Recipient. <i>Mycopathologia</i> , 2020, 185, 399-403.	1.3	5
17	Early antibiotic use is associated with CMV risk and outcomes following allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2020, 4, 6364-6367.	2.5	5
18	1103. Respiratory Virus Infections In Solid Organ Transplant Recipients: A Single Center Experience. <i>Open Forum Infectious Diseases</i> , 2020, 7, S581-S582.	0.4	0

#	ARTICLE	IF	CITATIONS
19	A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of <i>Clostridium difficile</i> associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2019, 68, 196-203.	2.9	41
20	Infectious Complications of Transplant Tourism. <i>Current Infectious Disease Reports</i> , 2019, 21, 36.	1.3	1
21	Use of maintenance therapy and incidence of recurrent Cytomegalovirus DNAemia among allogeneic hematopoietic cell transplant recipients. <i>Transplant Infectious Disease</i> , 2019, 21, e13054.	0.7	5
22	Saddle Nose Deformity in an Immunosuppressed Patient. <i>Clinical Infectious Diseases</i> , 2019, 68, 705-709.	2.9	2
23	Intestinal parasites including <i>Cryptosporidium</i> , <i>Cyclospora</i> , <i>Giardia</i> , and <i>Microsporidia</i> , <i>Entamoeba histolytica</i> , <i>Strongyloides</i> , Schistosomiasis, and <i>Echinococcus</i> : Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clinical Transplantation</i> , 2019, 33, e13618.	0.8	60
24	Tissue and blood protozoa including toxoplasmosis, Chagas disease, leishmaniasis, <i>Babesia</i> , <i>Acanthamoeba</i> , <i>Balamuthia</i> , and <i>Naegleria</i> in solid organ transplant recipients” Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clinical Transplantation</i> , 2019, 33, e13546.	0.8	79
25	Bloodstream infection caused by enteric organisms during the first 6 months after intestinal transplant. <i>Transplant Infectious Disease</i> , 2019, 21, e13064.	0.7	5
26	Solid organ transplantation from Zika IgM positive donors: Not always a true positive. <i>Clinical Transplantation</i> , 2019, 33, e13492.	0.8	0
27	Implementation of a <i>Strongyloides</i> screening strategy in solid organ transplant donors and recipients. <i>Clinical Transplantation</i> , 2019, 33, e13497.	0.8	21
28	2696. Breakthrough Toxoplasmosis While on Atovaquone Prophylaxis Following Allogeneic Hematologic Stem Cell Transplantation. <i>Open Forum Infectious Diseases</i> , 2019, 6, S948-S948.	0.4	1
29	Nontuberculous mycobacteria in solid organ transplant. <i>Current Opinion in Organ Transplantation</i> , 2019, 24, 476-482.	0.8	11
30	How Clean Is the Linen at My Hospital? The Mucorales on Unclean Linen Discovery Study of Large United States Transplant and Cancer Centers. <i>Clinical Infectious Diseases</i> , 2019, 68, 850-853.	2.9	31
31	Next-generation sequencing of microbial cell-free DNA for rapid noninvasive diagnosis of infectious diseases in immunocompromised hosts. <i>F1000Research</i> , 2019, 8, 1194.	0.8	37
32	Arboviruses Recommendations for Solid-Organ Transplant Recipients and Donors. <i>Transplantation</i> , 2018, 102, S42-S51.	0.5	19
33	Recommendations for Management of Endemic Diseases and Travel Medicine in Solid-Organ Transplant Recipients and Donors. <i>Transplantation</i> , 2018, 102, 193-208.	0.5	53
34	A cluster of donor-derived <i>Cryptococcus neoformans</i> infection affecting lung, liver, and kidney transplant recipients: Case report and review of literature. <i>Transplant Infectious Disease</i> , 2018, 20, e12836.	0.7	22
35	2395. Mechanism-Based-Susceptibility Testing (MBST) Using Disc Diffusion Assays (DDA) to Guide Treatment of Multidrug- and Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> (MDR-XDR-Pa) in a Cystic Fibrosis (CF) Lung Transplant Recipient; Are We Ready for Combination Therapy vs. MDR-XDR-Pa?. <i>Open Forum Infectious Diseases</i> , 2018, 5, S714-S714.	0.4	0
36	How can we improve the outcome for transplant patients with nontuberculous mycobacterial infections?. <i>Future Microbiology</i> , 2018, 13, 903-914.	1.0	6

#	ARTICLE	IF	CITATIONS
37	Impact of Cytomegalovirus Viral Load on Probability of Spontaneous Clearance and Response to Preemptive Therapy in Allogeneic Stem Cell Transplantation Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 806-814.	2.0	46
38	Unique characteristics of cryptococcosis identified after death in patients with liver cirrhosis: comparison with concurrent cohort diagnosed antemortem. <i>Medical Mycology</i> , 2017, 55, myw079.	0.3	4
39	Clinical outcomes of intestinal transplant recipients colonized with multidrug-resistant organisms: a retrospective study. <i>Transplant International</i> , 2017, 30, 924-931.	0.8	13
40	Severe hypertension after initiation of rifapentine/isoniazid for latent tuberculosis in renal transplant candidates. <i>Transplant International</i> , 2017, 30, 108-109.	0.8	7
41	Transplant center support for infectious diseases. <i>Transplant Infectious Disease</i> , 2017, 19, e12746.	0.7	3
42	Impact of Viral Load on Eradication of Cytomegalovirus (CMV) Viremia Amongst High-risk Allogeneic Stem Cell Transplant (SCT) Recipients. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	2
43	The use of brincidofovir for the treatment of mixed dsDNA viral infection. <i>Journal of Clinical Virology</i> , 2016, 83, 1-4.	1.6	23
44	Impact of antiretroviral therapy on clinical outcomes in HIV+ kidney transplant recipients: Review of 58 cases. <i>F1000Research</i> , 2016, 5, 2893.	0.8	24
45	Successful Treatment of Carbapenemase-Producing Pandrug-Resistant <i>Klebsiella pneumoniae</i> Bacteremia. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5903-5908.	1.4	54
46	Predictors of Immune Reconstitution Syndrome in Organ Transplant Recipients With Cryptococcosis: Implications for the Management of Immunosuppression. <i>Clinical Infectious Diseases</i> , 2015, 60, 36-44.	2.9	79
47	Candidemia in the critically ill: initial therapy and outcome in mechanically ventilated patients. <i>BMC Anesthesiology</i> , 2013, 13, 37.	0.7	10
48	Infections Transmitted by Transplantation. <i>Infectious Disease Clinics of North America</i> , 2010, 24, 497-514.	1.9	47
49	Posaconazole: A new oral antifungal agent with an expanded spectrum of activity. <i>American Journal of Health-System Pharmacy</i> , 2009, 66, 225-236.	0.5	32
50	Echinocandins in the management of invasive fungal infections, part 2. <i>American Journal of Health-System Pharmacy</i> , 2006, 63, 1813-1820.	0.5	37
51	Echinocandins in the management of invasive fungal infections, part 1. <i>American Journal of Health-System Pharmacy</i> , 2006, 63, 1693-1703.	0.5	68